![](/img/cover-not-exists.png)
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer
Mohamed Abu-Hamar, Abd El Halim, Mansour, Saleh, El Shebiney, Mohamed, El Bary, Naser Mohamed Abd, Sadaka, Emad, Maria, AlaaVolume:
3
Language:
english
Journal:
Hematology/Oncology and Stem Cell Therapy
DOI:
10.1016/s1658-3876(10)50022-0
Date:
July, 2010
File:
PDF, 263 KB
english, 2010